PharmaPendium® Adds New Module to Aid Decision Making on Drug Candidates

PharmaPendium Metabolizing Enzymes and Transporters Module delivers comprehensive visibility of Drug-Drug-Interactions

Amsterdam, May 6, 2013

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.

The addition of the Metabolizing Enzymes and Transporters Module to PharmaPendium’s existing content gives researchers a greater understanding and visibility of Drug-Drug Interactions (DDI) and their potential adverse reactions during critical stages of drug discovery and development.

The new module will benefit researchers including toxicologists, pharmacokinetics researchers and departments, safety pharmacologists and clinical pharmacologists, who demand the highest quality data on preclinical and clinical metabolizing enzymes and transporters. These researchers often struggle to find comparative data to understand how changes in the activity of metabolizing enzymes and transporters affect the safety and efficacy of drugs. Currently, available information on DDIs is hard to collate and analyze and is not always normalized for comparison, making data analysis not only labour and cost intensive, but also open to critical error.

PharmaPendium’s Metabolizing Enzymes and Transporters Module allows for rapid, full text-search of literature from sources including approval documents from the Food and Drug Administration (FDA) and European Medicines Agency (EMA). It extracts both in vivo and in vitro human and animalexperimental data on metabolizing enzymes and transporters contained in preclinical and clinical studies, and applies it to the context of researchers’ experiments, facilitating efficient and diligent drug development.

“Identifying potential interactions that impact the efficacy and safety of a drug is a significant challenge,” said Philip MacLaughlin, Director of Product Development at Elsevier. “The new module supports early detection of viable drug candidates by providing the highest quality data and enabling comparative assessments of metabolizing enzyme and transporter activities, reducing chances of unpredictable adverse reactions and even late stage clinical failures.”

PharmaPendium is part of Elsevier’s Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow, including Reaxys, Reaxys Medicinal Chemistry, ScienceDirect, Scopus, TargetInsights, Pathway Studio and Embase.

PharmaPendium Metabolizing Enzymes and Transporters Module is available now; for more information go to: www.elsevier.com/pharmapendium

# # #

About PharmaPendium
PharmaPendium decision support tool allows safety assessment teams, toxicologists, pharmacokineticists and project leaders to extract relevant comparative pharmacological and pharmacokinetic information from the entire history of drug development by locating published regulatory and commercial precedents sharing similarities with the class, the target or the structural chemistry of candidate drugs. This allows R&D organizations to make faster, more reliable decisions about which candidate compounds to take forward to pre-clinical phases. www.elsevier.com/pharmapendium

PharmaPendium
® and the PharmaPendium® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Liz Griffioen
Elsevier
+31 20 485 2247
l.griffioen@elsevier.com